Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer.

BACKGROUND Mucinous carcinoma of the colon and rectum (mucinous CRC) is a histological subtype of colorectal adenocarcinoma for which there is little data on chemotherapy responsiveness. The purpose of this study was to investigate specifically the efficacy of fluorouracil-based first-line chemotherapy in patients with advanced mucinous CRC. PATIENTS AND METHODS All patients with advanced mucinous CRC enrolled in three prospective randomized trials evaluating infused 5-fluorouracil as first-line treatment were compared with patients with non-mucinous subtypes enrolled in the same trials in a case-control study. Prognostic factors associated with overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) were identified using univariate and multivariate logistic and/or Cox proportional hazards analyses. RESULTS The study included 135 patients (45 cases and 90 controls). The response rates for cases and controls were 22% [95% confidence interval (CI), 11% to 38%] and 47% (95% CI, 36.1% to 58.2%), respectively (P=0.0058). Median OS for the mucinous CRC patients was 11.8 months (95% CI, 8.87-14.8) compared with 17.9 months (95% CI, 13.38-22.39) in the control group (univariate analysis, P=0.056); after correcting for significant prognostic factors by multivariate Cox regression analysis, P=0.0372 and hazard ratio (HR)=1.497 (1.02-2.19). CONCLUSION Patients with advanced mucinous CRC have a poorer response to fluorouracil-based first-line chemotherapy and reduced survival compared with patients with non-mucinous CRC.

[1]  M. Gore,et al.  Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  V. Gouyer,et al.  Differential mucin expression in colon carcinoma HT‐29 clones with variable resistance to 5‐fluorouracil and methotrexate , 2004, Biology of the cell.

[3]  T. Hickish,et al.  Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. , 2004, Clinical colorectal cancer.

[4]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Daniel J Sargent,et al.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Daniel J Sargent,et al.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.

[7]  R. Labianca,et al.  Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[9]  M. Meyers,et al.  Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. , 2001, Cancer research.

[10]  J. Guillem,et al.  Signet-ring cell carcinoma of the colon and rectum: a matched control study. , 1998, Diseases of the colon and rectum.

[11]  A. Padhani,et al.  A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  F. Vitelli,et al.  Microsatellite instability in sporadic mucinous colorectal carcinomas: relationship to clinico‐pathological variables , 1997, The Journal of pathology.

[13]  H. Stein,et al.  Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast, and ovary , 1997, The Journal of pathology.

[14]  H. Stein,et al.  Low frequency of p53 gene mutation and protein expression in mucinous colorectal carcinomas. , 1996, Cancer letters.

[15]  R. Gafà,et al.  p53 expression in colorectal cancer: relation to tumor type, DNA ploidy pattern and short-term survival. , 1996, American journal of clinical pathology.

[16]  C. Hanski.  Is mucinous carcinoma of the colorectum a distinct genetic entity? , 1995, British Journal of Cancer.

[17]  T. Hickish,et al.  Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Silvestrini,et al.  p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers , 1995, The Journal of pathology.

[19]  Kathleen R. Cho,et al.  The DCC gene product in cellular differentiation and colorectal tumorigenesis. , 1994, Genes & development.

[20]  Tomokazu Hoshi,et al.  Frequent K‐ras mutations and absence of p53 mutations in mucin‐producing tumors of the pancreas , 1994, Journal of surgical oncology.

[21]  A. Marchetti,et al.  p53 Mutations and Histologie Type of Invasive Breast Carcinoma , 1993, Cancer research.

[22]  H. Kitchener,et al.  p53 mutation is a common genetic event in ovarian carcinoma. , 1993, Cancer research.

[23]  R. Dahiya,et al.  Heterogeneity of mucin gene expression in normal and neoplastic tissues. , 1993, Cancer research.

[24]  J. Meyer,et al.  Mucinous component in colorectal carcinoma—prognostic significance: A study in a south Indian population , 1992, Journal of surgical oncology.

[25]  G. Thomas,et al.  Association of ki‐ras mutation with differentiation and tumor‐formation pathways in colorectal carcinoma , 1991, International journal of cancer.

[26]  A. Recht,et al.  Colloid carcinoma of the colon and rectum , 1987, Cancer.

[27]  R. Williamson,et al.  Peculiarities of mucinous colorectal carcinoma , 1985, The British journal of surgery.

[28]  S. George,et al.  The natural history of colorectal carcinoma in adolescents , 1982, Cancer.

[29]  J. Coindre,et al.  The prognostic significance of specific histologic features of carcinoma of the colon and rectum. , 1981, Surgery, gynecology & obstetrics.

[30]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .

[31]  D. Symonds,et al.  Mucinous carcinoma of the colon and rectum , 1976, Cancer.

[32]  D. Parham.  COLLOID CARCINOMA. , 2022, Annals of surgery.